Company Overview and News

Dilipkumar Vishindas Lakhi buys 1.31 lakh shares of TRF

2016-01-30 moneycontrol
Dilipkumar Vishindas Lakhi bought 131,912 shares of TRF at Rs 295.25 per share on the NSE...

Taiwan to punish nine banks on yuan derivative business

[TAIPEI] Taiwan's Financial Supervisory Commission (FSC) said it will punish nine banks for inappropriately selling yuan derivative product to clients, in its latest effort to prevent further defaults. Read more at The Business Times.

Games Countries Play

2015-11-30 seekingalpha
Calls for International coordination of macroeconomic policy are back, after a 30-year hiatus. To some it looks anomalous that the Fed is about to raise interest rates at a time when most major centra

Why Invest In Emerging Market Small Cap Stocks?

2015-11-02 seekingalpha
The notion of a “small-cap premium” is deeply established in investors’ consciousness. Many investors include an explicit allocation to U.S. and international small-cap stocks in their portfolios in o

Opportunities In Crisis: Why Emerging Markets Still Make Great Investments

2015-10-15 seekingalpha
Current trends indicate this is a fragile state for emerging markets. However, this current concern about these markets is actually an opportunity to invest in opportunities and stronger prospects. Th

Eurozone unemployment 11%, CPI slips back into negative territory

2015-09-30 seekingalpha
Eurozone unemployment held steady at 11% in August vs forecasts of 10.9%. (PR) CPI -0.1% in September vs +0.1% in August and vs consensus of unchanged. Core CPI stays at +0.9% on year, as expected. (

ECB's latest economic bulletin

2015-09-17 seekingalpha

Eurozone growth revised upwards, Japan contracts less than thought

2015-09-08 seekingalpha
Eurozone Q2 GDP growth has been revised up to 0.4% on quarter from an initial estimate of 0.3%, boosted by household consumption and exports. GDP expanded 0.5% in Q1. (PR) Meanwhile, Japan's economy

Eurozone growth revised upwards, Japan contracts less than thought

2015-09-08 seekingalpha
Eurozone Q2 GDP growth has been revised up to 0.4% on quarter from an initial estimate of 0.3%, boosted by household consumption and exports. GDP expanded 0.5% in Q1. (PR) Meanwhile, Japan's economy

Eurozone factory growth lower than expected

2015-09-01 seekingalpha
Eurozone manufacturing growth eased last month, despite factories barely raising prices, adding to the ECB's woes as it battles to spur expansion and inflation.Markit's final manufacturing Purchasing

Eurozone manufacturing PMI stays flat in August

2015-08-21 seekingalpha
The widely watched eurozone manufacturing PMI for August remained flat at 52.4, matching the previous month, although the figure was slightly better than the 52.2 reading of economists due to a strong

Capital exodus from the emerging markets

2015-08-19 seekingalpha
A slump in emerging market confidence has led to $1T in capital outflows over the past 13 months, roughly double the amount that fled during the financial crisis.The sustained exodus of capital highli

Eastern Europe's Post-2004 Convergence With EU: Financialisation

2015-07-22 seekingalpha
In the previous post, I covered the EU's latest report on real economic convergence in Central & Eastern European (CEE10) Accession states. As promised, here is a look at the last remaining core d

Eastern Europe's Post-2004 Convergence With EU: Unimpressive To-Date

2015-07-22 seekingalpha
The EU Commission's latest report on real economic convergence in the EU10 Accession states of Eastern and Central Europe (CEE10) sounds like a cheerful reading on successes of the EU and the euro. Th

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...